Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy

Progress in Cardiovascular Diseases(2024)10.1016/j.pcad.2024.12.010Source: DataRank Database

Anti-consumption agents: Tirzepatide and semaglutide for treating obesity-related diseases and addictions, and improving life expectancy is a research paper published in Progress in Cardiovascular Diseases (2024). On theSindex it has a DataRank of 0. It has been cited 33 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access33 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 10.68)OA: hybridTopics (46)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

William Grant Franco,Evan L. O’Keefe ORCID,James H. O’Keefe ORCID

Live enrichment

PubMed:39743126 PMC:PMC12103286 OpenAlex:https://openalex.org/W4405910234

National Institutes of Health

Grant: T32HL110837

National Institutes of Health

Grant: 79260132

National Heart, Lung, and Blood Institute

FWCI

10.68

Citation Percentile

1.0%

Citation Trend

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.pcad.2024.12.010

publisherhttps://doi.org/10.1016/j.pcad.2024.12.010

publisherhttps://api.elsevier.com/content/article/PII:S0033062024001798?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0033062024001798?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39743126

Fields of Study

Pharmacology and Obesity TreatmentDiabetes Treatment and ManagementDiet and metabolism studiesHumansObesityGlucagon-Like PeptidesLife ExpectancySubstance-Related DisordersTreatment OutcomeAnti-Obesity AgentsBehavior, AddictiveAnimalsTirzepatideGlucagon-Like Peptide 1Semaglutide

MeSH Terms

TirzepatideSemaglutideAnimalsGlucagon-Like PeptidesHumansLife ExpectancyObesityBehavior, AddictiveTreatment OutcomeAnti-Obesity AgentsSubstance-Related DisordersGlucagon-Like Peptide 1

Keywords

MedicineSemaglutideLife expectancyAddictionConsumption (sociology)ObesityExpectancy theoryGerontologyPsychiatryEnvironmental healthType 2 diabetesDiabetes mellitusSocial psychologyInternal medicineEndocrinologyPopulationSurvivalDiabetesTirzepatide

Sustainable Development Goals

SDG 0: Zero hunger